TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6896649
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine (0.2 mg kg‐1 in 0.9% saline)
Study: 6896649
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (0.2 mg kg‐1 in 0.9% saline)
Study: 31194778
Drug: Oral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatments (risperidone, olanzapine)
Study: 31194778
Drug: Oral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatments (clozapine, olanzapine)
Study: 31194778
Drug: Long-acting treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting treatment switched from another long-acting
Study: 29701875
Drug: Treatment (dengue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (dengue vaccine)
Study: 17057048
Drug: Full-dose TIV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose TIV (n = 222)
Study: 17057048
Drug: Half-dose TIV
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose TIV (n = 222)
Study: 9240642
Drug: Postoperative inguinofemoral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative inguinofemoral radiation therapy (Group 1, 65 patients)
Study: 9240642
Drug: No inguinofemoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inguinofemoral radiation therapy (Group 2, 70 patients)
Study: 8252455
Drug: Aminophylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (2 mg/kg, i.v.)
Study: 25712760
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri Prodentis (one tablet every 24 hours for 30 days)
Study: 25712760
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered after probiotic treatment for 6 months)
Study: 21771281
Drug: Vardenafil (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (starting dose 10 mg, titratable to 5 mg or 20 mg after 4 weeks)
Study: 16923005
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) in patients with prior RVAP (Group A)
Study: 16923005
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) in patients without prior RVAP (Group B)
Study: 14698860
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of methylprednisolone
Study: 3524436
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BW942C and TMP-SMX
Study: 29370942
Drug: Analgesic consumption
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic consumption
Study: 24108237
Drug: Control (Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Amlodipine monotherapy)
Study: 20332721
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) injection in triceps surae muscles
Study: 18164245
Drug: Nolomirole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolomirole (5 mg b.i.d.)
Study: 17051490
Drug: Azithromycin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (750 mg twice daily) + Artesunate (100 mg twice daily)
Study: 17051490
Drug: Azithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1000 mg once daily) + Artesunate (200 mg once daily)
Study: 17051490
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg 3 times daily) + Quinine (10 mg/kg 3 times daily)
Study: 17051490
Drug: Azithromycin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (750 mg twice daily) + Quinine (10 mg/kg twice daily)
Study: 12743434
Drug: Omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole MUPS 40 mg
Study: 11187917
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose cytarabine with high-dose methotrexate during interval therapy (trial 58881)
Study: 11187917
Drug: Leukocyte counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte counts >100 x 10(9)/l, specific genetic abnormalities, poor initial response to steroids, high level of minimal residual disease (trial 58881)
Study: 8466005
Drug: 0.9 micrograms.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 micrograms.kg‐1.min‐1 of intravenous nitroglycerin
Study: 28071044
Drug: 3.0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/d CLA for 12 weeks
Study: 23670305
Drug: SBR759 (3‐,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759 (3‐, 6‐, 9‐, 12‐g/day)
Study: 23670305
Drug: Placebo (12‐g/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12‐g/day)
Study: 18759356
Drug: CP-101,606 (NR2B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-101,606 (NR2B selective NMDA glutamate antagonist)
Study: 15821528
Drug: Duloxetine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (80 mg daily) + Pelvic Floor Muscle Training (PFMT)
Study: 15821528
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Duloxetine + PFMT)
Study: 1681224
Drug: Long-acting chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting chloramphenicol (double injection on admission and 48 hours later)
Study: 1681224
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin (8 days, 4 times a day)
Study: 6619812
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of inactivated hepatitis B vaccine (20 micrograms) by automatic jet injection
Study: 22480620
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injections
Study: 21968360
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 h)
Study: 19793213
Drug: CORT (Corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORT (Corticosteroid injections)
Study: 17999899
Drug: Thrombolytic drugs
Normalized name: INVESTIGATIONAL THROMBOLYTIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic drugs administered intraventricularly through an external ventricular drain
Study: 9809092
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml of 0.5% hyperbaric bupivacaine solution
Study: 9809092
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.5% hyperbaric bupivacaine solution
Study: 9809092
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 0.5% hyperbaric bupivacaine solution
Study: 7534838
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group B)
Study: 31505302
Drug: Local retropharyngeal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local retropharyngeal steroids
Study: 31505302
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no retropharyngeal steroids)
Study: 22320714
Drug: 5000 ppm
Normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5000 ppm F; twice a day
Study: 22320714
Drug: 5000 ppm;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 ppm; twice a day, plus the 'massage' method once a day
Study: 22320714
Drug: 1450 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 ppm F; twice a day
Study: 22320714
Drug: 1450 ppm;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1450 ppm; twice a day, plus the 'massage' method once a day
Study: 21490522
Drug: S-ketamine infusion
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine infusion at 2 μg · kg · min for 3 hrs
Study: 21490522
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion at equivalent rate for 3 hrs
Study: 22189657
Drug: S-ketamine infusion
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine infusion
Study: 17668562
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment switch
Study: 17668562
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment switch
Study: 11125195
Drug: 1,100 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 ppm fluoride dentifrice (Winterfresh Gel)
Study: 9586886
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 8 million U subcutaneously daily
Study: 9586886
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 1 million U subcutaneously daily
Study: 3132930
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid infusion alone
Study: 28634748
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg in combination with 80 mg/m2 paclitaxel
Study: 28634748
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with 80 mg/m2 paclitaxel
Study: 21122391
Drug: Interleukin-11 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-11 (50 µg × kg(‐1) × d(‐1))
Study: 12820332
Drug: Adjuvant autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant autologous tumor cell lysate vaccine
Study: 9211627
Drug: Isradipine (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5mg daily for 4 weeks)
Study: 2823859
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of fish oil daily (1.8 g eicosapentaenoic acid)
Study: 2823859
Drug: Placebo supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement containing olive oil (iso-energetic)
Study: 16798303
Drug: Oral citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral citrulline (1.9 g/m2 per dose, 5 perioperative doses)
Study: 9660042
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.2 mg/kg
Study: 9174878
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 3 micrograms/kg
Study: 29482597
Drug: General Psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Psychiatric Management (GPM) treatment for BPD
Study: 27562743
Drug: Short cycle
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cycle therapy (5 days on, 2 days off ART)
Study: 27562743
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (continuous ART)
Study: 27562743
Drug: Short cycle
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cycle therapy
Study: 22767410
Drug: Transdiagnostic cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive-behavioral group treatment (12 weeks)
Study: 22767410
Drug: Diagnosis-specific group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis-specific group Cognitive-Behavioral Therapy (CBT) protocols (12 weeks)
Study: 9426079
Drug: Inhaled phosphoramidon
Normalized name: phosphoramidic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled phosphoramidon (10[-5] M)
Study: 7506155
Drug: Bromeline (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromeline (240 mg/day)
Study: 30930132
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (20 mg/kg body weight)
Study: 30930132
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation with nitrate (7 mg/kg body weight) and vitamin C
Study: 30930132
Drug: Nitrate (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate (7 mg/kg body weight)
Study: 25901838
Drug: 33-G needle
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33-G needle
Study: 25901838
Drug: 30-G needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-G needle
Study: 16875654
Drug: Antibiotics (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (metronidazole 250 mg and erythromycin 250 mg at 20 to 24 weeks of gestation 3 times daily for 7 days and metronidazole 250 mg and ampicillin 500 mg every 4 hours during labor)
Study: 12548304
Drug: Soya scones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya scones (120 mg/day of isoflavones)
Study: 10861339
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris (3.21 mg per kg body weight daily)
Study: 3703176
Drug: PK 8165
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 8165 (50, 100, 150 mg)
Study: 3703176
Drug: Control session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control session (no treatment)
Study: 29926988
Drug: Galantamine 8
Normalized name: galantamine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 8 mg/day
Study: 28069279
Drug: Masitinib (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (6 mg/kg per day over 24 weeks)
Study: 26308758
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (20 mg of omeprazole, 1g of amoxicillin, 500 mg of metronidazole, and 400 mg of bismuth compound for 7 days)
Study: 26308758
Drug: Pylorex Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pylorex Plus (500 mg for 15 days)
Study: 18713259
Drug: Adjunctive antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antimicrobial photodynamic therapy (aPDT)
Study: 18713259
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (with and without adjunctive aPDT)
Study: 16365181
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in CALGB studies for extensive-stage small-cell lung cancer
Study: 12941995
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination therapy regimen 1
Study: 12941995
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination therapy regimen 2
Study: 11055467
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (beta-blockers and diuretics)
Study: 31630249
Drug: Intra-esophageal injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-esophageal injection of 10 mL of thickened water at 10 mL/s
Study: 31630249
Drug: Intra-esophageal injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-esophageal injection of 3 mL of thickened water at 10 mL/s
Study: 31630249
Drug: Intra-esophageal injection
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-esophageal injection in the upper region
Study: 26651478
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioural therapy
Study: 26651478
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavioural therapy
Study: 17926617
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) plus behavior therapy
Study: 14693413
Drug: Acarbose (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (titrated to a maximum of 100mg three times daily)
Study: 14693413
Drug: Tolbutamide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide (titrated to a maximum of 2000 mg in three doses)
Study: 11204938
Drug: Novofem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novofem (1 mg estradiol + 1 mg norethisterone acetate)
Study: 11204938
Drug: Activelle (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activelle (1 mg estradiol + 0.5 mg norethisterone acetate)
Study: 7530064
Drug: N,G‐nitro‐L‐arginine methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: N,G‐nitro‐L‐arginine methyl ester (L‐NAME)
Study: 31126277
Drug: Complex on-site
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex on-site intervention including physician visits, nursing staff involvement, computerized documentation system (CoCare Cockpit), joint trainings and audits, structured treatment paths, after-hours medical care availability.
Study: 31126277
Drug: Care/treatment as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care/treatment as usual (control group).
Study: 24918474
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of Physical Activity (PPA)
Study: 23743809
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with indapamide sustained release 1.5 mg +/- perindopril 2-4 mg
Study: 9186346
Drug: Sialyl Lewis(x)
Normalized name: sialyl Lewis A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sialyl Lewis(x) molecules
Study: 7903213
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg once daily
Study: 29223479
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab with anthracycline-containing chemotherapy (FEC)
Study: 29223479
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab with anthracycline-free chemotherapy (docetaxel)
Study: 27177615
Drug: Chlorella (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorella (5 g/d)
Study: 11465710
Drug: Diclofenac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac + Misoprostol (75 mg diclofenac + 200 microg misoprostol twice daily for 6 weeks)
Study: 11465710
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg acetaminophen 4 times daily for 6 weeks)
Study: 31607603
Drug: Standard-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose oral Rotarix vaccine
Study: 31607603
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral Rotarix vaccine
Study: 30076113
Drug: IV rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV rt-PA treatment for patients with body weight >100 kg
Study: 26437613
Drug: Chamomile tea
Normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile tea (3 g/150 mL hot water) 3 times per day immediately after meals for 8 weeks
Study: 3100007
Drug: Diltiazem 360
Normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 360 mg
Study: 21423055
Drug: n‐3FA supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3FA supplements (stopped an average of 2.3 days before surgery)
Study: 21423055
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no n‐3FA supplements)
Study: 21423055
Drug: n‐3FA supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3FA supplements
Study: 15747149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2D and 3D ultrasound
Study: 8684301
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to MMMF and other agents
Study: 361068
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg twice daily) for 4 to 17 weeks
Study: 361068
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet twice daily) for 4 to 12 weeks
Study: 28478317
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group B)
Study: 15074084
Drug: Yangxue Qingnao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxue Qingnao granule (YXQN) plus conventional medical treatment
Study: 15074084
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment alone
Study: 8198932
Drug: [S]-leucovorin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: [S]-leucovorin (300 mg m-2)
Study: 8198932
Drug: rac-leucovorin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: rac-leucovorin (600 mg m-2)
Study: 2822879
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril daily
Study: 2822879
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 10 mg enalapril (low-dose combination)
Study: 29862395
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement based on Lippia citriodora and Hibiscus sabdariffa polyphenolic extracts
Study: 26257041
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation (UAS) system implantation, first implant (n=22)